Personalized therapy is directed at obtaining maximal therapeutic effect on diseased tissue
with minimal off-target side effects. Many classes of therapeutics have attempted to reach …

As a result of the escalating number of new cancer treatments being developed and
competition among pharmaceutical companies, decisions regarding how to proceed with …

Sipuleucel-T, the first autologous active cellular immunotherapy approved by the United
States Food and Drug Administration, is designed to stimulate an immune response to …

Longitudinal changes of tumor size or tumor-associated biomarkers have been receiving
growing attention as early markers of treatment benefits. Tumor growth inhibition-overall …

The primary end point of this study was to determine the safety and feasibility of
intraprostatic administration of PSA-TRICOM vaccine [encoding transgenes for prostate …

Background Nintedanib in combination with docetaxel is approved in the European Union
and other countries for the treatment of patients with advanced non-small-cell lung cancer …

Antibody drug conjugates (ADCs) provide targeted delivery of cytotoxic agents directly
inside tumor cells. However, many ADCs targeting solid tumors have exhibited limited …

ABSTRACT T-cell receptor alternate reading frame protein (TARP) is a 58-residue protein
over-expressed in prostate and breast cancer. We investigated TARP peptide vaccination's …

Background The US FDA and the EMA have approved seven agents for the treatment of
renal cell carcinoma, primarily based on differences in progression-free survival (PFS) …

Early tumor assessments have been widely used to predict overall survival (OS), with
potential application to dose selection and early go/no‐go decisions. Most published tumor …